The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -15,099 | -25,020 |
| Depreciation and amortization | 416 | 851 |
| Stock-based compensation expense | 984 | 1,863 |
| Change in fair value of derivative tranche liability | -1,800 | - |
| Impairment of right-of-use asset | 494 | - |
| Loss on the sale of property and equipment | -67 | - |
| Non-cash lease expense | 489 | 954 |
| Non-cash interest and other expenses | 1 | 16 |
| Prepaid expenses and other current assets | 419 | -310 |
| Accounts payable | -546 | -15 |
| Accrued expenses and other liabilities | 1,362 | -1,755 |
| Deferred revenue | 0 | -385 |
| Operating lease assets and liabilities | 766 | 1,448 |
| Net cash used in operating activities | -11,217 | -24,629 |
| Purchases of property and equipment | 0 | 279 |
| Proceeds from the sale of property and equipment | 36 | - |
| Net cash used in investing activities | 36 | -279 |
| Proceeds from issuance of common stock and pre-funded warrants, net | 32,562 | - |
| Proceeds allocated to the derivative tranche liability | 14,930 | - |
| Proceeds from exercise of stock options | 3 | - |
| Principal payments on finance leases | 14 | 79 |
| Proceeds from issuance of common stock | - | 0 |
| Principal payments on financing obligation | 97 | 0 |
| Payments of deferred offering costs | 0 | 0 |
| Net cash provided by (used in) financing activities | 47,384 | -79 |
| Net change in cash, cash equivalents, and restricted cash | 36,203 | -24,987 |
| Cash and cash equivalents at beginning of period | 65,663 | - |
| Cash and cash equivalents at end of period | 76,879 | - |
Camp4 Therapeutics Corp (CAMP)
Camp4 Therapeutics Corp (CAMP)